Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This session will focus on clinical indications and basics of medical physics and radiobiology (along with Dr. Hobbs). Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed. The purpose of the Radiopharmaceuticals Refresher is to increase physician, physicist, and trainee understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical and clinical physicists, and medical oncologists.
Upon completion of this activity, participants should be able to do the following:
- Discuss the relevant principles of physics and radiobiology for radiopharmaceutical therapies (RPTs).
- Identify clinical indications for RPTs that are currently approved for clinical use.
- Identify barriers and logistical steps for implementing RPT use in their own practice.
Robert Francois Hobbs, PhD, is employed by Johns Hopkins Medicine and has received honoraria from AA/Novartis and copyright/patent/license/royalty from RAPID Dosimetry. He serves in a leadership position with AAPM.
Ana Kiess, MD, PhD, is employed by Johns Hopkins Medicine and has received grant/research funding from Bayer, Merck, Novartis/AA and had an uncompensated relationship with POINT. She serves in a leadership position with the ABR.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.